Prakt. lékáren. 2019; 15(2): 70-73 | DOI: 10.36290/lek.2019.013
New treatment options for relapsing-remitting multiple sclerosis
- Centrum demyelinizačních onemocnění při neurologickém oddělení Nemocnice Jihlava
In recent years, the treatment options for relapsing-remitting multiple sclerosis have expanded considerably. Cladribine and ocrelizumab are novel drugs intended for the treatment of patients with the active form of this chronic disease. Both drugs have been shown to have a high efficacy in large clinical trials in which there was a reduction in the clinical and radiological activity of multiple sclerosis compared with placebo or active comparator. In comparison with the commonly used current treatment, both drugs have an attractive administration pattern that increases patient adherence to treatment. The safety profile is favourable, with no case of progressive multifocal leukoencephalopathy or another opportunistic infection having been observed in neither of the drugs without prior treatment with another immunomodulatory drug.
Keywords: multiple sclerosis, ocrelizumab, cladribine, immune reconstitution therapy
Published: June 20, 2019 Show citation
References
- Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018 Apr 21; 391(10130): 1622-1636.
Go to original source... 
Go to PubMed... - Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000 Sep 28; 343(13): 938-952. Go to original source... Go to PubMed...
- Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014 Sep 9; 83(11): 1022-1024. Go to original source... Go to PubMed...
- Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb; 17(2): 162-173. Go to original source... Go to PubMed...
- Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017 Dec; 264(12): 2351-2374. Go to original source... Go to PubMed...
- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar Or A, Comi G, De Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P and Wolinsky JS, for the ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. NEJM Org., December 21, 2016. Go to original source... Go to PubMed...
- Hauser SL, Bar Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H and Kappos L, for the OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. NEJM Org., December 21, 2016, DOI: 10.1056/NEJMoa1601277. Go to original source... Go to PubMed...
- Mulero P, Midaglia L and Xavier Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018; 11: 1756286418773025. Go to original source... Go to PubMed...
- Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011 Jan-Feb; 34(1): 28-35. Go to original source... Go to PubMed...
- Boyko A, Boyko O. Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul, DiS. 2018; 8: 35-44. Go to original source... Go to PubMed...
- Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg S?rensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4; 362(5): 416-426. Go to original source... Go to PubMed...
- Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler. 2018 Apr 1: 1352458518771875. Go to original source... Go to PubMed...
- Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K4 Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018 Oct; 24(12): 1594-1604. Go to original source... Go to PubMed...